Biodesix | GenomeWeb

Biodesix

The deal gives the firm access to Bioyong's network of hospital-installed mass specs on which it hopes to place assays including its Veristrat lung cancer test.

Studies presented at the recent SITC annual meeting indicate the company's MALDI-based proteomic tests could help guide checkpoint inhibitor treatment.

The company said Humana, Medical Mutual of Ohio, and PreferredOne will now cover the non-small cell lung cancer test for their 11.5 million members.

Recently presented studies support the utility of Genestrat and Veristrat for detecting actionable mutations and guiding therapy in drug-resistant lung cancer patients.

Clinical lab supply firm Streck will exclusively supply Biodesix with DNA and RNA tubes, including its lines of blood collection tubes.

Horizon BCBS of New Jersey, which covers 3.8 million people in that state, began covering the test for patients with non-small cell lung cancer on May 10, 2016.

BlueCross BlueShield of Florida began covering the test on March 15, and Health Care Services Corporation will begin coverage in June.

Norgen Biotek's sample prep  products are already used in Biodesix's GeneStrat liquid biopsy assay workflow.

The company said it will use the funds to continue developing new companion diagnostics and expand commercialization of its VeriStrat and GeneStrat products

The company last year launched a PCR-based assay for identifying mutations in lung cancer patients and plans to release an NGS-based test later this year.

Pages

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.